JF
ALLO icon

Jump Financial’s Allogene Therapeutics ALLO Stock Holding History

Jump Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-169,348
Closed -$395K – 1606
2024
Q2 		$395K Buy
169,348
+155,050
+1,084% +$457K 0.01% 1234
2024
Q1 		$63.9K Buy
+14,298
New +$59.7K ﹤0.01% 1820
2023
Q2 		– Sell
-219,762
Closed -$1.09M – 1765
2023
Q1 		$1.09M Buy
219,762
+111,213
+102% +$713K 0.04% 566
2022
Q4 		$683K Sell
108,549
-17,817
-14% -$165K 0.04% 653
2022
Q3 		$1.36M Buy
+126,366
New +$1.72M 0.05% 495
2022
Q2 		– Sell
-130,880
Closed -$1.19M – 1583
2022
Q1 		$1.19M Buy
+130,880
New +$1.36M 0.05% 462
2021
Q1 		– Sell
-37,000
Closed -$934K – 910
2020
Q4 		$934K Buy
+37,000
New +$1.21M 0.16% 168

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jump Financial's ALLO Position: Q3 2024 in Review

Jump Financial sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 169,348 shares — an estimated $395K sold.

Jump Financial first reported a position in ALLO in Q4 2020 and held it in 7 quarters. The position peaked at $1.36M in Q3 2022. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Jump Financial reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jump Financial sold 169,348 Allogene Therapeutics shares in Q3 2024, an estimated $395K.
  • Jump Financial first reported a position in Allogene Therapeutics in Q4 2020 and held it in 7 quarters.
  • Jump Financial's Allogene Therapeutics position peaked at $1.36M in Q3 2022.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Jump Financial's 13F filing for Q3 2024, filed 14 Nov 2024.